Manufacturer introduction of Rubicatin/Rubitidine

Lurbinectedin is a new type of anti-tumor drug that is an RNA polymerase II inhibitor and is mainly used to treat refractory tumors such as small cell lung cancer (SCLC). The drug was originally developed by PharmaMar, S.A., a Spanish biopharmaceutical company. It is one of the few companies in the world that focuses on anti-cancer drugs derived from marine natural products. PharmaMar's R&D strategy is highly specialized and innovative, using marine microorganisms as the basis for drug discovery, and through complex chemical synthesis and screening processes, it has successfully launched a variety of anti-cancer drugs including rubicatin.

PharmaMar was founded in 1986 as part of the Grupo Zeltia Group and has complete drug development, manufacturing, quality control and international registration capabilities. The company is committed to the development of innovative drugs in the field of tumor treatment. Its star products Yondelis (tegafur) and rubitidine have both been approved by European and American drug regulatory agencies. In the development of rubitidine, PharmaMar used its exclusive patented synthesis process and precise target screening strategy to greatly improve the drug's efficacy and selectivity, especially showing significant efficacy against DNA repair-deficient tumors.

Currently, rubitin has received accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of small cell lung cancer that has relapsed after platinum-based chemotherapy. At the same time,PharmaMar is continuing to advance its indication expansion in a variety of solid tumors, including ovarian cancer, breast cancer, and sarcoma. In the Chinese market, rubitinthe original drug has been introduced and launched by cooperative enterprises. Although it has not yet been included in medical insurance, its efficacy advantages and market potential are gradually emerging. PharmaMar is establishing its differentiated position in the global oncology drug market with its strong R&D capabilities and unique marine drug platform. Rubitidine is also regarded as a key part of its globalization strategy.

Reference materials:https://www.zepzelca.com/